Literature DB >> 27246587

Pulmonary manifestations of Sjögren's syndrome.

Thomas Flament1, Adrien Bigot2, Benjamin Chaigne2, Helene Henique3, Elisabeth Diot2, Sylvain Marchand-Adam4.   

Abstract

In 9-20% of cases, Sjögren's syndrome is associated with various respiratory symptoms. The most typical manifestations are chronic interstitial lung disease (ILD) and tracheobronchial disease. The most common manifestation of ILD is nonspecific interstitial pneumonia in its fibrosing variant. Other types of ILD, such as organising pneumonia, usual interstitial pneumonia and lymphocytic interstitial pneumonitis, are rare. Their radiological presentation is less distinctive, and definitive diagnosis may require the use of transbronchial or surgical lung biopsy. Corticosteroid therapy is the mainstay of ILD treatment in Sjögren's syndrome, but the use of other immunosuppressive drugs needs to be determined. ILD is a significant cause of death in Sjögren's syndrome. Tracheobronchial disease is common in Sjögren's syndrome, characterised by diffuse lymphocytic infiltration of the airway. It is sometimes responsible for a crippling chronic cough. It can also present in the form of bronchial hyperresponsiveness, bronchiectasis, bronchiolitis or recurrent respiratory infections. The management of these manifestations may require treatment for dryness and/or inflammation of the airways. Airway disease has little effect on respiratory function and is rarely the cause of death in Sjögren's syndrome patients. Rare respiratory complications such as amyloidosis, lymphoma or pulmonary hypertension should not be disregarded in Sjögren's syndrome patients.
Copyright ©ERS 2016.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27246587     DOI: 10.1183/16000617.0011-2016

Source DB:  PubMed          Journal:  Eur Respir Rev        ISSN: 0905-9180


  50 in total

Review 1.  The Diagnosis and Treatment of Sjögren's Syndrome.

Authors:  Ana-Luisa Stefanski; Christian Tomiak; Uwe Pleyer; Thomas Dietrich; Gerd Rüdiger Burmester; Thomas Dörner
Journal:  Dtsch Arztebl Int       Date:  2017-05-26       Impact factor: 5.594

2.  Systemic manifestations of primary Sjögren's syndrome in the NOD.B10Sn-H2b/J mouse model.

Authors:  Jeremy Kiripolsky; Long Shen; Yichen Liang; Alisa Li; Lakshmanan Suresh; Yun Lian; Quan-Zhen Li; Daniel P Gaile; Jill M Kramer
Journal:  Clin Immunol       Date:  2017-05-17       Impact factor: 3.969

3.  Echogenic lymph nodes in the differential diagnosis of pediatric sarcoidosis.

Authors:  Zuhal Bayramoglu; Ibrahim Adaletli; Ezgi Kara; Manolya Acar; Selda Hancerli Torun; Ozge Kaba; Ayper Somer; Gulcin Yegen; Sidar Bagbudar; Rukiye Eker Omeroglu
Journal:  J Med Ultrason (2001)       Date:  2019-02-08       Impact factor: 1.314

4.  Interstitial Lung Disease Associated with Connective Tissue Diseases.

Authors:  Ruben A Peredo; Vivek Mehta; Scott Beegle
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

5.  Recommendations for evaluation and diagnosis of extra-glandular manifestations of primary sjogren syndrome: results of an epidemiologic systematic review/meta-analysis and a consensus guideline from the Brazilian Society of Rheumatology (articular, pulmonary and renal).

Authors:  Virginia Fernandes Moça Trevisani; Alisson Pugliesi; Sandra Gofinet Pasoto; Maria Lucia Lemos Lopes; Lissiane Karine Noronha Guedes; Samira Tatiyama Miyamoto; Marilena Leal Mesquita Silvestre Fernandes; Sonia Cristina de Magalhães Souza Fialho; Aysa César Pinheiro; Laura Caldas Dos Santos; Simone Appenzeller; Tania Fidelix; Sandra Lúcia Euzébio Ribeiro; Danielle Christinne Soares Egypto de Brito; Tatiana Nayara Libório-Kimura; Maria Carmen Lopes Ferreira Silva Santos; Diego Ustárroz Cantali; Juliana D'Agostino Gennari; Vinicius Tassoni Civile; Ana Carolina Pereira Nunes Pinto; César Ramos Rocha-Filho; Fabiola Reis Oliveira; Aline Pereira da Rocha; Valeria Valim
Journal:  Adv Rheumatol       Date:  2022-06-01

6.  KL-6 as a Biomarker of Interstitial Lung Disease Development in Patients with Sjögren Syndrome: A Retrospective Case-Control Study.

Authors:  Yu-Hsiang Chiu; Chen-Chih Chu; Chun-Chi Lu; Feng-Cheng Liu; Shin-En Tang; Shi-Jye Chu; San-Yuan Kuo; Hsiang-Cheng Chen
Journal:  J Inflamm Res       Date:  2022-04-08

7.  Altered levels of circulating CD8+CXCR5+PD-1+T follicular cytotoxic cells in primary Sjögren's syndrome.

Authors:  Xuwen Zhai; Yanlin Wang; Hui Guo; Zhaojun Liang; Min Feng; Yanyao Wu; Yan Qin; Xiangcong Zhao; Chong Gao; Jing Luo
Journal:  Clin Rheumatol       Date:  2022-02-16       Impact factor: 2.980

Review 8.  Metastatic Angiosarcoma of the Scalp Presenting with Cystic Lung Lesions: A Case Report and Review of Cystic Lung Diseases.

Authors:  Antonette A Ajayi; Stephanie V Commins; David E Clarke
Journal:  Perm J       Date:  2018

9.  A retrospective analysis of distinguishing features of chest HRCT and clinical manifestation in primary Sjögren's syndrome-related interstitial lung disease in a Chinese population.

Authors:  Xin Dong; Junfei Zhou; Xiaojuan Guo; Yifan Li; Yuetong Xu; Qiang Fu; Yong Lu; Yi Zheng
Journal:  Clin Rheumatol       Date:  2018-09-22       Impact factor: 2.980

Review 10.  A patient with primary Sjogren's syndrome, cystic lung disease, and MALT lymphoma treated successfully with rituximab: a case-based review.

Authors:  Leanna M Wise; Daniel G Arkfeld
Journal:  Clin Rheumatol       Date:  2019-12-20       Impact factor: 2.980

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.